Although many kinds of therapies are applied in the clinic, drug-resistance is a major and
unavoidable problem. Another disturbing statistic is the limited number of drug targets, which …

The discovery of cytokines as key drivers of immune-mediated diseases has spurred efforts
to target their associated signalling pathways. Janus kinases (JAKs) are essential signalling …

PURPOSE Despite undergoing allogeneic hematopoietic stem cell transplantation (HCT),
patients with acute myeloid leukemia (AML) with internal tandem duplication mutation in the …

Background Patients with acute myeloid leukemia (AML) and a FLT3 mutation have poor
outcomes. We conducted a phase 3 trial to determine whether the addition of midostaurin …

The FMS-like tyrosine kinase 3 (FLT3) gene is mutated in approximately one third of patients
with acute myeloid leukemia (AML), either by internal tandem duplications (FLT3-ITD), or by …

Protease-targeted chimeras (PROTACs) are a new technology that is receiving much
attention in the treatment of diseases. The mechanism is to inhibit protein function by …

The outlook for patients with acute myeloid leukaemia has improved in the past 30 years.
Unlike other cancers, much of this progress is attributable to refinement of supportive …

Opinion statement Approximately 40–45% of younger and 10–20% of older adults with
acute myeloid leukemia (AML) will be cured with current standard chemotherapy. The …

Abstract Patients received 5-azacytidine (AZA) 75 mg/m2 intravenously daily for 7 days and
sorafenib 400 mg orally twice daily continuously; cycles were repeated at∼ 1-month …

Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults, with an
incidence that increases with age, and a generally poor prognosis. The disease is clinically …